Xcout Intel
Arrivo BioVentures, LLC
Arrivo BioVentures, LLC is a biopharmaceutical holding company that provides management oversight, funding, and intellectual property development for subsidiaries targeting hard-to-treat diseases. The company's clinical-stage pipeline includes drug candidates for major depressive disorder and severe acute pancreatitis.
Subscribe to see Arrivo BioVentures, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Arrivo BioVentures, LLC at a glance
Arrivo BioVentures, LLC is a biotechnology company headquartered in United States. It has raised at least $88.5M across the 2 funding rounds on record. Its most recent funding round raised $43.2M in November 2023. Xcout tracks 10 named people at Arrivo BioVentures, LLC, including Kelly Abernathy (Chief Operating Officer).
Arrivo BioVentures, LLC leadership
- Kelly AbernathyChief Operating Officer
- Karen AdamsChief Financial Officer
- Joel RaskinChief Medical Officer
- Stephen E. ButtsChief Executive Officer
- Greg RigdonSenior Vice President Scientific Affairs
- John HixonHead of Corporate Development
4 more named people on record for Arrivo BioVentures, LLC, with roles, board committees and tenure — see the full roster →
Arrivo BioVentures, LLC funding rounds
At least $88.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $43.2M | — | |
| Series B | $45.3M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Arrivo BioVentures, LLC competitors
A few of Arrivo BioVentures, LLC's closest competitors — see the full list of competitors and alternatives →
Neurawell Therapeutics is a clinical-stage research and development company that develops central nervous system (CNS) treatments. It focuses on addressing unmet medical needs for patients suffering from conditions such as depression, major depressive disorder, treatment-resistant depression, anxiety, and neurological disorders like Parkinson's disease.
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company. It is dedicated to developing rapid-acting treatments for neuropsychiatric diseases.
Evecxia, Inc. is a holding and therapeutics company founded in 2013 and based in North Carolina, focusing on drug pipelines, patents, and clinical trials for neuropsychiatric conditions.
VivaMed BioPharma is a clinical-stage biopharmaceutical company that develops new chemical entities and repurposed drugs. It serves the healthcare and research sectors by advancing therapies across neurology, pain, psychiatry, pulmonology, and rheumatology through global partnerships and operator-led development.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Get Arrivo BioVentures, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Arrivo BioVentures, LLC in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access